Physiomics Share Discussion Threads

[davevt] 10/10/2023 12:18

No, it's still 11.

End of the day, all you care about, is the sell price.

Is the sell price higher than what you paid? No. Then who cares.

[412069] 10/10/2023 11:41

Which is closing as it rises.

[davevt] 10/10/2023 11:35

No, it's an 11% spread.

[412069] 10/10/2023 11:31

Is this rise down to the up and coming VAL & 201 deal ?

[davevt] 09/10/2023 09:21

Share, you need to re post my rebuttal again.

[davevt] 08/10/2023 20:51

I know, their 'dosing tool' still isn't finished and it's been 3 years now..

3 years...

[share14] 08/10/2023 18:03

It's a good point dave, why is it if they say, "we are going to try this" anyone would believe they're going to make a success of it? They've got no track record for it, in fact quite the opposite. They things they've already tried have yielded nothing else but a paltry revenue and losses despite lots of noise. How have they earned any credibility?

[davevt] 08/10/2023 12:50

Ah I said, it doesn't matter what they can add...their competitors are leagues ahead of them. all of them do what pyc can only dream of doing.

This is the problem with those over on lse....they seem to forget pyc is about ten years behind everyone else.

If pharmas want Biostatistics, there are plenty of companies that are already doing it..so why use pyc?

[porky9] 08/10/2023 03:47

thanks for the vote of confidence @thiopia

thanks @davevt noted the LSE posting point
I don't think this play is a dead duck, they clearly have some decent paying contracts, they just don't have enough of them for the cash burn.
They are active in the sector, what they need is to diversify and offer other services in addition, just not sure biostats is enough but its what else could you add? That's the thing.

[davevt] 07/10/2023 18:41

Tip, if you start a thread on LSe, don't make your first post something that they could get deleted...make it the second post.

Reason being is if you start a thread, and make say ten replies in that thread...if they remove the first post it removes the entire thread and any replies made in it.

[share14] 07/10/2023 13:39

@porky

They're real lowlifes on lse to get people's posts removed. These people have destroyed these boards which could have been a great way for private investors to help each other. Any time I'm interested in a share I have to wade through hundreds of rampy posts just to get to something interesting. Any time there's a decent poster who's negative about a stock they get called a troll and get their posts removed.

Don't expect your post on the PYC board to stick around. I've had dozens removed just for pointing out Laura's figures are make believe.

[davevt] 07/10/2023 10:23

I personally don't think they will get anywhere...simply because other drug dosing companies already exist, and they will dose for all types of drugs, not only cancer ones.

If I was a pharma needing drug dosing, surely I'm gonna choose one that can do all the drugs I make.

Not only that, I'm sure these multi billion dollar companies surely have their own tech to do this in house.

Remember, we really don't know 'how' pyc manage to get a contract. Maybe a lot are done for free, hence no fee shown. They simply may say 'let us do this for you so we can make an rns out of it'...

[porky9] 07/10/2023 04:32

@share14
Personally, I'm starting to contribute less and less on any of these forums for the exact same reasons as you. I have been active on the Valirx board here and at LSE as my research notes are detailed and I can add value from an evaluation perspective but on all these boards, LSE is far far worse, they offer little value to evaluate and discuss with other investors. Over there they even request removal of posts that don't agree. The moderators then often just delete the entire threads for speed. Almost a total waste of time contributing. What's the point in that??

You cant discuss properly anything about the investee business because the installed cheerleaders just wont have any of it, they just want echo chambers and be comforted by others that think the same way and just there to ramp. Over on LSE earlier the cheerleader @Laura2022 is telling everyone PYC will get £6m from VAL. I mean i ask you, utterly ridiculous.

But you are right that nobody will quantify anything i totally agree. Its just how it is, you have to Do your own research frankly, might as well keep it to yourself.


@Davevt
Thanks for your reply earlier. Everything you say is totally logical. From a quick check on google there are approximately 1,400 Biotech Businesses in the UK that carry our Drug R&D so that is Jim's market. As you say, perfectly feasible for a rep to visit each one in person over 20 years....

These businesses like PYC are clueless about sales and marketing, same over on Valirx, they will go and have a jolly at a trade show and consider that a good use of capital yet there are far more effective ways to reach that audience.

My observation is that Jim is a reasonably hard working good guy that is constantly spinning plates, probably talking to the Biotech, working on the tenders through to taking an active part in the drug modeling itself and probably ordering more toilet roll for the bog on his way out the door at night. He is the knowledge. I have seen this so many times in other businesses.

Also, In a Biotech financial squeeze, there is clearly less actual new business about and much business on hold so... It looked to me that prior to the drought, they were close to BE i was expecting that to happen and over the last two years the financial squeeze got worse pushing him further back. BUT i do think BE is achievable it's possible which then whist not revolutionary in its own right, at least puts investors minds at rest that they wont be on for yet another cash call.

So I come back to the burning question, how do we add exponential growth to this business??. IF cash was available what would he do with it to grow this?

Biostats modeling opens another consultancy area hence the new guy but more consultancy work whilst needed, is not the answer IMO. Its all labour intensive and the value of consultancy plays is minimal, like 1x Revenue so the current share price is probably right, 1p to 2p that's our lot. BUT what Jim does have at least is a good installed client base to work from.

So to make this business more exciting, what are the expansion areas, clearly AI and product dev like Beyond Blood looks a winner, has anyone here any thoughts??? IF i could think of a fit here frankly i would go to Jim with it. What type of business can be acquired here to help materially advance this play?

[tees maar khan] 06/10/2023 18:38

share14, The biotech slump hasn't helped a lot of companies. Physiomics aren't alone? I've criticised and blamed the CEO. He is responsible for the underperformance, but it's not all his fault. A lot is out of his control. Why do you constantly feel the need to isolate and run down the company? as if they are the only company that has been affected. There is a lot more opportunity now to grow the business. The placing is well out of the way. They'll try to get non-dilutive funding/grants moving forward.

TMK

[share14] 06/10/2023 11:56

I'm pretty much retired now. Cry me a river. Love the way clowns like you get butthurt at people pointing out the flaws with this stock, but don't say anything about the management behind the decimated share price. Own your losses.

[share14] 06/10/2023 11:30

Another butthurt numpty. Those who are clueless about how businesses work invest in long term loss making companies. Own your losses clown.

share14 18 Apr '22 - 20:22 - 10044 of 11320
The software company I founded got a similar sized contract after 2 years from a larger company than Merck with 3 years of maintenance and updates on top.

[thiopia] 06/10/2023 10:34

Figures.

Those who can, do.
Those who can't, teach.
Those too useless to teach, work in 'regulation'

share14 5 Oct '23 - 12:00 - 11309 of 11318

Neither do I, it's why I contacted the FCA as something very whiffy is going on. (I used to work in financial market regulation)

[davevt] 06/10/2023 10:05

The thing is this company has been going 20 years, and still can't make any decent revenues, let alone profit...so I don't actually believe it's model is to make a profit..I think it's designed to bubble under and pay itself through placings and grants.

It's a bit like when they put out an rns saying they are going to a show to try and get new business...surely in 20 years everyone in the industry must know what they do, and that they exist. Surely in 20 years they could have visited in person every potential customers and get on the radar?

So either this hasn't, and they are utterly incompetent, or they have, and companies don't want to use them...most likely because they are already doing it themselves, or using a competitor..who doesnt just do cancer drugs only.

Jim worked for GSK...yet hasn't got them as a customer. Why?

[porky9] 06/10/2023 05:02

@Davevt
Appreciate you taking the time out to post your thoughts and evaluations you clearly have completed some quality research. I respect that, as when investing i want to know the complete picture, good and bad, LSE is just becoming an echo chamber.

Anyhow, from my perspective, i like Jim as a CEO as he gives me the impression he is an honest broker and he draws a conservative salary whilst the business builds, he is not taking SH for fools IMO but my main concern with this business is the very nature that its really a "Consulting" business. He wins a consulting contract valued at X over Y period and that's it. they then have to keep quoting and winning new consulting contracts as the old ones fizzle out. So the business faces constant high level churn and on the new side client acquisition costs are high and take time to win.

Its not like a SaaS Software company where you get ongoing recurring annual renewals, with this one, yes he hopes to get another drug from the existing client to consult on and build modeling for but in a bear market like this current one biotechs have less budget hence new projects harder to come by.

So to combat above Jim states he will diversify and to do that provide a Biostats offering, i totally get that. So he hires the new bod to offer this additional service. Guessing this will take some time to establish?

Bit i would like your help on @Davevt is how you think we get to a position where the business gets to break even so it no longer relies on SH placing cash?

Without stating the obvious, win more new clients to evaluate on the modeling side, I get that but is there something they could acquire? Do they need a CRO for example or is there some other associated business that complements what they do to add here?

I have been thinking a lot about this, if i thought adding x business to this offering would complement / help them i would seriously consider connecting Jim with the right support to add X to get the entire business profitable.

I would hate to see the ultimate demise of this business but it cant keep relying on placing hand outs continually that's for sure. I would value your opinion specifically in this regard.

[shortcpx] 05/10/2023 22:47

Laura Ryden?

[share14] 05/10/2023 20:56

Good spot Dave.

We can clearly see the agenda to mislead people over on lse. Funny thing is Piddler has been doing it for years and got nowhere.